Back to top

Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial

Phathom Pharmaceuticals (PHAT) announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating Voquezna tablets as a...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Phathom Pharmaceuticals, Inc. (PHAT)